옵션 체인은 다양한 행사가격과 만기일에 대한 Design Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Design Therapeutics에 대한 시장 심리를 평가합니다..

Design Therapeutics (NASDAQ:DSGN) 주식, 옵션 체인

Design Therapeutics

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Design Therapeutics Inc

WestPark Capital analyst Curtis Shauger initiates coverage on Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Buy rating and announces Price Target of $315.

News

Price Target

Initiation

Analyst Ratings

WDAY

WestPark Capital Initiates Coverage On Workday with Buy Rating, Announces Price Target of $315

Howard Lutnick, the U.S. Commerce Secretary, has voiced his concerns regarding the likelihood of a trade agreement with Canada ahead of a&nbsp;meeting between President&nbsp;Donald Trump and the newly elected Canadian Prime Minister&nbsp;Mark Carney on Tuesday.
What Happened: On Monday, Lutnick referred to the Canadian government as a &#8220;socialist regime&#8221; and questioned the feasibility of a trade deal with the country.
During an interview with Fox Business Network's Larry Kudlow, he pointed out that the U.S. has been disproportionately supporting the Canadian economy for decades, with American companies manufacturing cars and producing films in Canada.
He called making a deal with Canada &#8220;really complex&#8221; and stated, &#8220;They&#8217;ve been basically feeding off of us for decades upon decades upon decades.&#8221;
Lutnick expressed anticipation for the upcoming meeting between the leaders of the two nations but also voiced his doubts about its potential success. &#8220;Its going to be a fascinating meeting.&#8221; The commerce secretary added, &#8220;I just don&#8217;t see how it works out so perfectly.&#8221;
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/05/45187521/buffett-tips-his-hat-to-tim-cooks-leadership-at-apple-he-has-made-berkshire-a-lot-more-money-than-ive-ever-made" target="_blank" rel="noreferrer noopener">Warren Buffett Says He Is &#8216;Embarrassed,&#8217; But &#8216;Tim Cook Has Made Berkshire A Lot More Money Than I&#8217;ve Ever Made&#8217;</a>
Why It Matters: Lutnick&#8217;s comment comes before a high-stakes meeting between the heads of the U.S. and Canada. On Friday, Canadian PM Mark Carney told reporters that he had a &#8216;very constructive&#8217; phone call with Trump and called him one of the &#8216;best negotiators&#8217;. Previously, Carney had asserted, &#8220;Our old relationship with the United States (&#8230;) is over.&#8221;
On Monday, when asked about the meeting with Carney, President Trump told reporters, &#8220;I&#8217;m not sure what he wants to see me about but I guess he wants to make a deal everybody does they all want to make a deal&#8221;
Notably, in April, Canada announced a temporary six-month relief from its countermeasure tariffs on U.S. goods, a move that signaled a de-escalation in North America&#8217;s trade standoff. The decision, which was in line with a more conciliatory tone recently struck by the Trump administration, was seen as a positive step towards easing trade tensions between the two countries.&nbsp;
However, Lutnick&#8217;s recent remarks have introduced a new level of uncertainty into the equation. As the leaders of the two nations prepare to meet, the outcome of their discussions could have significant implications for the future of U.S.-Canada trade relations.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="President Trump will change the way trade is done, Commerce secretary says" width="500" height="281" src="https://www.youtube.com/embed/zF5JJiDx32M?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/events/25/04/44971154/trump-fails-to-impress-americas-young-shows-poll-as-they-still-favor-biden-only-15-think-us-on-right-track" target="_blank" rel="noreferrer noopener">Trump Fails To Impress America&#8217;s Young, Shows Poll As They Still Favor Biden — Only 15% Think US On Right Track &#8211; Benzinga</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Government

Politics

US Commerce Secretary Lutnick Skeptical Of Trade Deal With Canada's 'Socialist Regime' Ahead Of Trump-Carney Meeting: 'They've Been Basically Feeding Off Of Us For Decades Upon Decades..'

Needham analyst Serge Belanger maintains Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) with a Buy and lowers the price target from $15 to $14.

OCUL

Needham Maintains Buy on Ocular Therapeutix, Lowers Price Target to $14

Haliey Welch, also known as the &#8220;Hawk Tuah Girl,&#8221; addressed the controversy surrounding her memecoin, which dropped in value shortly after launch, prompting holders to file a lawsuit against her team.&nbsp;&nbsp;
What happened: During an interview <a href="https://www.vanityfair.com/hollywood/story/haliey-welch-aka-hawk-tuah-tries-to-explain-herself">with</a> Vanity Fair on Friday, the viral influencer expressed regret and emotional distress over the incident, stating that she didn&#8217;t fully understand cryptocurrency.
"Half of those people that done it were, like, my fans. They trusted me, like, guiding them to it. And I don't know…it really hurt my feelings when it turned out the way it did. I wish it hadn't have [sic] happened," Welch said.
She admits to knowing very little about cryptocurrency and should have done more research before beginning such a venture.&nbsp;
"You got to be really careful what you tie your name to, and you definitely need to know what you're getting yourself into when you agree to do it," Welch said.&nbsp;
The ‘Hawk Tuah Girl' said she took a "much-needed" mental health break from the public eye after the controversy
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/25/05/45187462/trump-denies-personal-profit-from-memecoin-venture-i-havent-even-looked">Trump Denies Personal Profit From Memecoin Venture: &#8216;I Haven&#8217;t Even Looked&#8217;</a>
Why It Matters: The Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)-based HAWK meme coin ballooned to a <a href="https://www.benzinga.com/general/entertainment/24/12/42333397/hawk-tuah-girl-accused-of-scamming-crypto-buyers-after-newly-launched-meme-coin-pumps-and-dumps-victims-contemplate-legal-action">$490 million market capitalization</a> shortly after its December launch before swiftly plunging 91%, leaving unsuspecting investors holding the bag.
On-chain detective Stephen Findeisen, better known as Coffeezilla, described the launch as one of the most &#8220;miserable and horrible&#8221; ever, alleging insider trading activity.
The team behind the token <a href="https://www.benzinga.com/content/42377682/coffeezilla-debunks-misleading-headlines-about-influencer-hailey-welch-and-hawk-memecoin">denied allegations of a rug pull</a>, a scam where creators raise funds for the coin, causing its value to soar only to disappear with the invested funds, leaving the project worthless.
According to a TMZ <a href="https://www.tmz.com/2025/03/27/haliey-welch-hawk-tuah-girl-meme-coin-investigation-over-sec-no-charges/">report</a> from March, Haley's attorney said that the SEC closed its investigation without taking any action against her.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45187736/elizabeth-warren-slams-shady-deal-involving-trump-family-backed-usd1-as-democrats-withdraw-support-for-senarte-crypto-bill">Elizabeth Warren Slams &#8216;Shady&#8217; Deal Involving Trump Family-Backed USD1 As Democrats Withdraw Support For Senate Crypto Bill</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Entertainment

Markets

$SOL

'Hawk Tuah Girl' Haliey Welch Expresses Regret Over Controversial Meme Coin Launch, Wishes It Hadn't Happened

Shares of ThredUp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) rose sharply in today's pre-market trading after the company announced better-than-expected first-quarter results and <a href="https://www.benzinga.com/quote/TDUP/earnings">raised its FY25 sales forecast</a>.
ThredUp posted a quarterly loss of 4 cents per share, compared to market estimates for a loss of 7 cents per share. The company's quarterly sales came in at $71.29 million versus expectations of $68.19 million.
ThredUp shares jumped 19.6% to $5.31 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>AIFU Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFU#NASDAQ">AIFU</a>) rose 76.4% to $0.2178 in pre-market trading after falling around 11% on Monday.</li>
<li>Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) surged 70.6% to $1.08 in pre-market trading after jumping around 12% on Monday.</li>
<li>China SXT Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) gained 64.5% to $2.32 in pre-market trading after dipping 38% on Monday.</li>
<li>BloomZ Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) jumped 53.4% to $0.2770 in pre-market trading after gaining 8% on Monday.</li>
<li>CAMP4 THERAPEUTICS CORPORATION (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) gained 44.3% to $2.77 in pre-market trading.</li>
<li>JBDI Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBDI#NASDAQ">JBDI</a>) surged 32.5% to $1.10 in pre-market trading after announcing a $1.0 million share repurchase program.</li>
<li>Intrepid Potash, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) gained 19.4% to $38.88 in pre-market trading following first-quarter results.</li>
<li>WeRide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) gained 13.1% to $7.75 in pre-market trading after the company announced it expanded its strategic partnership with Uber to bring autonomous vehicles to 15 additional cities.</li>
<li>Pony AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) climbed 11.8% to $10.85 in pre-market trading. PONY AI and Uber announced a strategic partnership to advance autonomous mobility.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Cadiz Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDZI#NASDAQ">CDZI</a>) shares dipped 37.4% to $1.81 in pre-market trading.</li>
<li>NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares fell 28.8% to $0.7821 in pre-market trading after jumping more than 130% on Monday.</li>
<li>BRC Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) shares fell 24.3% to $1.79 in pre-market trading after posting a wider-than-expected quarterly loss.</li>
<li>N2OFF, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NITO#NASDAQ">NITO</a>) fell 22.7% to $0.5250 in pre-market trading after jumping 140% on Monday.</li>
<li>Digital Ally, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) declined 21.6% to $0.0250 in pre-market trading. Digital Ally, on Monday, announced a reverse stock split.</li>
<li>Energys Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGS#NASDAQ">ENGS</a>) shares tumbled 19.1% to $2.50 in pre-market trading after dipping 66% on Monday.</li>
<li>Hyperscale Data, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#NYSE">GPUS</a>) dipped 17.2% to $6.42 in pre-market trading. Hyperscale Data shares jumped 466% on Monday after the company issued FY25 sales guidance.</li>
<li>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) fell 8.4% to $113.45 in pre-market trading. Palantir reported in-line earnings for its first quarter on Monday. Palantir reported first-quarter revenue of $883.86 million, beating analyst estimates of $862.83 million. The company reported first-quarter adjusted earnings of 13 cents per share, in line with analyst estimates. The company also raised its full-year guidance</li>
<li>Arcus Biosciences, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>) fell 7.1% to $8.31 in pre-market trading.</li>
<li>Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) fell 6.8% to $206.00 in today's pre-market trading after the company reported third-quarter results and issued fourth-quarter guidance with its midpoint below estimates.</li>
</ul>
Now Read This:
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more"> Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Movers

Trading Ideas

AIFU

BLMZ

BRCC

CAMP

CDZI

DGLY

ENGS

GPUS

JBDI

MRIN

NCNA

NITO

PLTR

PONY

RCUS

SXTC

TDUP

Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

Needham analyst James Ricchiuti maintains NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) with a Buy and lowers the price target from $37 to $32.

NSSC

Needham Maintains Buy on NAPCO Security Techs, Lowers Price Target to $32

Gold prices climbed above $3,380 per ounce Tuesday, reaching a new high as investors sought safe-haven assets amid escalating trade tensions. The precious metal gained $90 in Monday&#8217;s session before adding another $45 in early trading.
What Happened: &#8220;Gold is up another $45 so far tonight, trading above $3,380. With today&#8217;s $90 gain, that&#8217;s already $135 within one 24-hour period,&#8221; noted economist Peter Schiff on X. &#8220;Silver is also starting to perk up. It&#8217;s adding another 50 cents to today&#8217;s gains, trading above $33.10. Keep an eye on silver. A breakout is near.&#8221;
The rally comes as President Donald Trump expanded tariffs, threatening 100% tariffs on foreign-produced films and announcing plans for pharmaceutical tariffs in the coming weeks. This follows already imposed steep 145% tariffs on Chinese goods that have rattled global markets.
Silver prices also surged nearly 2% to around $33 per ounce on Tuesday, extending gains from the previous session. In response to a follower suggesting silver needs to top $36 before moving to $50, Schiff replied, &#8220;I&#8217;d say a close above $35 would trigger that move.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Gold is up another $45 so far tonight, trading above $3,380. With today&#39;s $90 gain, that&#39;s already $135 within one 24-hour period. Silver is also starting to perk up. It&#39;s adding another 50 cents to today&#39;s gains, trading above $33.10. Keep an eye on silver. A breakout is near.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1919574440033055075?ref_src=twsrc%5Etfw">May 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/25/05/45212767/bitcoin-ethereum-flat-dogecoin-dips-even-as-trump-calls-crypto-popular-analyst-says-btc-build-up-good-predicts-eth-uptrend-after-fed-meet">Bitcoin, Ethereum Flat, Dogecoin Dips Even As Trump Calls Crypto &#8216;Popular:&#8217; Analyst Says BTC Build-up Good, Predicts ETH Uptrend After Fed Meet</a>
Why It Matters: Investors now await the Federal Reserve&#8217;s policy decision this week. Despite pressure from Trump to lower rates, the central bank is expected to maintain current interest rates. According to the CME FedWatch tool, markets are pricing in a 97% probability of rates remaining unchanged.
Gold-backed cryptocurrencies have benefited from the metal&#8217;s performance, with PAX Gold (PAXG) and Tether Gold extending their year-to-date gains to over 28%. Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) has shown comparatively modest growth at just 1.24% year-to-date, now trading around $94,000.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45214653/uber-could-win-the-robo-taxi-war-says-expert-analyst-predicts-75-gains-on-ride-hailing-cost-drop">Uber Could Win The &#8216;Robo Taxi War,&#8217; Says Expert: Analyst Predicts 75% Gains On Ride Hailing Cost Drop</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with&nbsp;the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was&nbsp;reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Commodities

$BTC

Bitcoin Critic Peter Schiff Says A 'Breakout Is Near' As Gold Surges Above $3,380, Silver Starts To Perk Up

Needham analyst Quinn Bolton maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Buy and lowers the price target from $57 to $50.

Needham Maintains Buy on ON Semiconductor, Lowers Price Target to $50

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and raises the price target from $15 to $17.

BCRX

Needham Maintains Buy on BioCryst Pharma, Raises Price Target to $17

President Donald Trump signed an executive order Monday directing the Food and Drug Administration to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to <a href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market">announce new tariffs on imported medicines</a> within two weeks
What Happened: The executive order aims to streamline the drug manufacturing approval process by eliminating unnecessary requirements and reducing the time needed to approve new U.S. production sites. 
According to the White House, building pharmaceutical manufacturing capacity currently takes &#8220;five to 10 years,&#8221; which it called &#8220;unacceptable from a national-security standpoint.&#8221;
&#8220;We don&#8217;t want to be buying our pharmaceuticals from other countries because if we&#8217;re in a war, we&#8217;re in a problem, we want to be able to make our own,&#8221; Trump said in a White House fact sheet.
See Also: <a href="https://www.benzinga.com/markets/25/05/45213562/peter-schiff-challenges-us-dominance-after-elon-musks-china-consumption-narrative-a-50-drop-in-the-dollar-could-supercharge-chinas-global-consumer-base">Peter Schiff Challenges US Dominance After Elon Musk&#8217;s China Consumption Narrative — A 50% Drop In The Dollar Could Supercharge China&#8217;s Global Consumer Base</a>
Why It Matters: The executive order comes as U.S. pharmaceutical manufacturing has significantly declined over decades, with most active drug ingredients now produced in China and other countries. According to EY analysis, reported by Reuters, the U.S. imported $203 billion in pharmaceutical products in 2023, with 73% coming from Europe, primarily Ireland, Germany and Switzerland.
For investors, this points to broader <a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target">shifts in the pharmaceutical secto</a>r, with companies such as Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), and AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) already unveiling new domestic manufacturing plans in reaction to the looming tariff threats.
The pending tariffs could significantly impact <a href="https://www.benzinga.com/personal-finance/25/04/45029761/experts-warn-tariffs-could-negatively-impact-pretty-fragile-supply-of-generic-drugs">generic drug makers</a>, which provide 90% of U.S. prescriptions, possibly worsening existing shortages. There are already over 250 drug shortages nationwide, down from 323 in early 2024 but still concerning for healthcare stakeholders.
Mark Cuban, whose Cost Plus Drugs company sells medications at substantial discounts, warned the tariffs could force <a href="https://www.benzinga.com/news/25/04/44658207/mark-cuban-says-cost-plus-drugs-faces-price-hike-threat-tariffs-would-force-us-to-pass-costs-directly-to-consumers">price increases on many drugs</a>: &#8220;If we have a high tariff on drugs coming from India, we won&#8217;t have a choice but to pass those costs on to consumers.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45213365/maxine-waters-to-obstruct-cryptocurrency-hearing-plans-shadow-hearing-instead">Maxine Waters Plans Walkout From Crypto Hearing, Will Host &#8216;Shadow Hearing&#8217; Opposing Trump Family Ventures: Report</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Equities

Regulations

Health Care

ABBV

Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns

Needham analyst Gil Blum maintains Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) with a Buy and lowers the price target from $11 to $8.

RXRX

Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $8

Macro Economic Events

Econ #s

Economics

U.K. Services Purchasing Managers Index For April 49.0 Vs. 48.9 Est.; 52.5 Prior

U.K. Composite Purchasing Managers' Index For April 48.5 Vs. 48.2 Est.; 51.5 Prior

Eurozone Services Purchasing Managers Index For April 50.1 Vs. 49.7 Est.; 51.0 Prior

Billionaire hedge‑fund manager Bill Ackman expects Washington's trade fight to fade quickly, stating that tariffs will amount to "a one‑time reset" rather than a new wave of inflation.
What Happened: &#8220;The important thing is the tariffs get resolved in the relative short term,&#8221; the Pershing Square CEO said, <a href="https://www.cnbc.com/2025/05/05/cnbc-excerpts-pershing-square-ceo-bill-ackman-speaks-with-cnbcs-andrew-ross-sorkin-on-squawk-box-today.html">speaking</a> at CNBC's &#8220;Squawk Box&#8221;. &#8220;If we're still dealing with the tariff thing as major headlines, that uncertainty will weigh on Q2.&#8221; Ackman argued that higher import duties would lift some prices, but unlike runaway inflation, the bump would not &#8220;compound.&#8221;
He sees a softer economy already taking shape. &#8220;I think inflation has largely been wrung out,&#8221; Ackman said, pointing to falling egg and energy costs. With price pressures cooling, he believes the Federal Reserve could begin trimming rates "toward the end of the year,&#8221; adding that &#8220;a small cut relatively soon … makes sense.&#8221;
Ackman blamed early‑year strength on &#8220;front‑loading of purchases&#8221; as companies tried to beat the Trump administration's 145% China tariff. <a href="https://www.benzinga.com/25/04/44616760/donald-trump-sets-reciprocal-tariffs-on-key-trade-partners-in-historic-policy-shock">&#8220;Liberation Day&#8221; uncertainty</a>, he said, prompted many firms to pause spending, momentum he expects to show up in second‑quarter data.
See also: <a href="https://www.benzinga.com/25/05/45213790/us-dollar-depreciation-is-cushioning-the-impact-of-tariffs-on-corporate-profits-says-expert-heres-how">US Dollar Depreciation Is Cushioning &#8216;The Impact Of Tariffs On Corporate Profits,&#8217; Says Expert</a>
On China policy, the investor urged a tempered approach: &#8220;The right thing to do is we pause on China — maybe 180 days," giving both sides room to strike a deal while U.S. companies shift supply chains.
Ackman has long criticized the Fed for keeping rates too high and famously <a href="https://www.benzinga.com/government/23/08/33547572/hedge-fund-guru-bill-ackman-bets-against-us-treasuries-expects-30-year-yields-to-surge-to-5-5">placed a bet</a> on falling Treasury yields in 2023. He says the bond market already senses a cooling economy this time, leaving policymakers little reason to wait.
Why It Matters: Ackman, last week, urged Trump on X to <a href="https://www.benzinga.com/markets/25/05/45160204/bill-ackman-presses-trump-to-pause-china-tariffs-says-time-becomes-our-friend-if-pressure-on-us-economy-is-lifted">suspend China tariffs</a>, saying they saddle U.S. firms with higher costs and drain Washington's leverage at the bargaining table. A pause, he argued, would flip the pressure onto Beijing because "every U.S. business is already moving its supply chain and manufacturing out of China."
 Ackman, who once endorsed Trump yet now <a href="https://www.benzinga.com/personal-finance/25/04/44778587/we-are-heading-for-a-self-induced-economic-nuclear-winter-billionaire-investor-bill-ackman-has-turned-on-trump-over-tariffs?utm_source=chatgpt.com">brands the duties</a> an "economic nuclear winter", issued the plea days after the White House hiked China levies to 125 percent while granting a 90‑day reprieve to non‑retaliating nations. He warned that smaller companies, lacking the cash buffers of multinationals, could <a href="https://www.benzinga.com/news/global/25/04/44723751/billionaire-investor-bill-ackman-praises-trumps-tariff-pause-thank-you-on-behalf-of-all-americans">buckle under prolonged tariffs</a>, undermining the economy Trump aims to shield.
Read next: <a href="https://www.benzinga.com/news/25/05/45214328/mike-pence-warns-trumps-indiscriminate-tariffs-could-trigger-price-shock-and-potential-shortages-keeping-our-kids-toys-affordable-is-part-of-the-american-dream">Mike Pence Warns Trump&#8217;s &#8216;Indiscriminate&#8217; Tariffs Could Trigger &#8216;Price Shock&#8217; And Potential Shortages: &#8216;Keeping Our Kids&#8217; Toys Affordable&#8230;Is Part Of The American Dream&#8217;</a>

Global

General

Bill Ackman Calls Tariffs A 'One Time Reset,' Warns Prolonged China Fight Could Drag Market Slump To Q2

HCOB Eurozone Composite Purchasing Managers Index For April 50.4 Vs. 50.1 Est.; 50.9 Prior

Germany Services Purchasing Managers Index For April 49.0 Vs. 48.8 Est.; 50.9 Prior

France Services Purchasing Managers Index For April 47.3 Vs. 46.8 Est.; 47.9 Prior

UBER

Pony AI Partners With Uber To Deploy Pony.ai's Robotaxis Onto The Uber Platform.

CAE Rebrands Portfolio Of Airline Operations Solutions To Flightscape – Powered By CAE

Earnings

Press Releases

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

Design Therapeutics to Participate in Leerink's Global Healthcare Conference

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Management

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

Comments

Design Therapeutics

Design Therapeutics (DSGN) 옵션

Design Therapeutics (NASDAQ:DSGN) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌